


I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on November 15, 2002

  
Glenn P. Ladwig, Patent Attorney



1632  
b26  
Dile  
6/26/02

INFORMATION DISCLOSURE  
STATEMENT  
Examining Group 1632  
Patent Application  
Docket No. USF-T135  
Serial No. 09/435,471

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Anne Marie Baker  
Art Unit : 1632  
Applicants : Denise R. Cooper, Niketa A. Patel  
Serial No. : 09/435,471  
Filed : November 8, 1999  
For : Glucose-Regulated mRNA Instability Element

**RECEIVED**

NOV 20 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231


INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

The applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669

GPL/mv

Attachments: Form PTO/SB/08; copies of references cited therein.